BioSpace News Archive

Business

Cedilla Therapeutics Expands Leadership Team with New Appointments to Direct Biology, Drug Discovery and Proteomics

Cedilla Therapeutics today formally announced the appointment of three vice presidents with extensive experience in drug discovery to advance the company’s mission of harnessing existing protein stability mechanisms to redirect the course of disease.

June 28, 2018
·
3 min read
Business

Walgreens Boots Alliance Reports Fiscal 2018 Third Quarter Results

Sales increased 14.0 percent to $34.3 billion

June 28, 2018
·
35 min read
Policy

Lipoprotein(a) Foundation Announces Two ICD-10 Diagnostic Codes for Elevated Lipoprotein(a) Approved by the CDC

New ICD-10 Codes Could Accelerate Access to Simple Blood Test for Elevated Lipoprotein(a) and Help Prevent Cardiovascular Events in People Whose Only Risk Factor is Lipoprotein(a).

June 28, 2018
·
4 min read
BioForest

Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 26, 2018

Seattle Genetics, Inc. announced today that it will report its second quarter financial results on Thursday, July 26, 2018 after the close of financial markets.

June 28, 2018
·
2 min read
Drug Development

Millendo Therapeutics Appoints Dr. Ryan Zeidan as Senior Vice President, Development and Strengthens Leadership Team with Key Promotions

Millendo Therapeutics, Inc. today announced the appointment of Ryan Zeidan, Ph.D., as Senior Vice President, Development.

June 28, 2018
·
2 min read
Business

Catalyst OrthoScience Adds Brian K. Hutchison to Board of Directors as Executive Chair, Interim CEO

Catalyst OrthoScience Inc. today announced the addition of Brian K. Hutchison to its board of directors as executive chair.

June 28, 2018
·
3 min read
Business

Appello Completes $10.5 Million Series A Financing Led by Deerfield Management and Mountain Group Partners

Investment initially to support innovative treatment of Parkinson’s disease

June 28, 2018
·
3 min read
Biotech Bay

McKesson Reaffirms Fiscal 2019 Guidance and Provides Preliminary Guidance for the First Quarter

The company also anticipates Adjusted Earnings per diluted share of approximately $2.85 to $2.95 for the first quarter of Fiscal 2019.

June 28, 2018
·
5 min read
Drug Development

Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting

Phase 3 clinical trial to evaluate rimegepant as a preventive therapy for migraine expected to begin by the fourth quarter of 2018

June 28, 2018
·
9 min read
Drug Development

PQ Bypass Reports Positive 12-Month Results for Entirely New Procedure to Treat Extremely Long SFA Lesions in Patients with PAD

DETOUR I Trial Presented during SVS Vascular Annual Meeting 2018 Late Breaking Clinical Trial Session

June 28, 2018
·
4 min read